Episode 29 - Scott Chetham and the Future of Clinical Trials

My guest in this episode is Scott Chetham. Scott is an experienced healthcare entrepreneur who is currently the CEO and co-founder of Faro Health. Scott leads the strategy for the Faro Health platform, which is designed to power clinical development by connecting data to decision making in a fundamentally new way. Previously, he was the Head of Clinical Research Operations and Data Management at Verily Life Sciences, formerly known as Google Life Sciences. His role involved leading the clinical strategy, clinical teams, process development and operations for all clinical projects of the company, including Google and Google[x]. Scott has also served as a Venture Partner at Versant Ventures, CTO and Co-founder of Intersection Medical (sold to ImpediMed), and VP Clinical Affairs (ImpediMed). In these latter two roles he was responsible for clinical research strategy and operations. In this deep dive discussion, Scott and I talk about surgical robots, patient recruitment difficulties for clinical trials, why he co-founded Faro Health, the current inefficiencies in clinical trials, how he and his colleagues are working to make it better and how they are using AI to do that, what the future clinical trails will look like, and the lessons he's learned as a tech and healthcare leader. I found my discussion with Scott very informative and timely. I hope you do too. Here's Scott Chetham.

You can listen to Episode 29 - Scott Chetham and the Future of Clinical Trials online on Radio and Podcast. Open the player on this page to stream the available audio.

Episode 29 - Scott Chetham and the Future of Clinical Trials is an episode from The Future of Pharma by Samir Gondalia, ISPE Boston.

This episode is 42:35 long.

This episode was published on Feb 12, 2025.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from The Future of Pharma when more episodes are available from the podcast feed.